Supernus Pharmaceuticals (SUPN) EBIT Margin (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly EBIT Margin of 26.46% for Q2 2026, down 3380.0% year-over-year from 0.81% in Q2 2025, and down 1321.95% on a QoQ basis from 1.86% in Q4 2025.
Supernus Pharmaceuticals (SUPN) EBIT Margin (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported EBIT Margin for 16 years, with the latest figure at 26.46% in Q2 2026.
- EBIT Margin for Q2 2026 came in at 26.46%, down 3380.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 13.95% (down 2360.0% YoY), and the FY2025 annual result was 8.66%, down 2100.0% from the prior year.
- EBIT Margin slipped to 26.46% in Q2 2026, from 1.86% in the prior quarter.
- Over five years, EBIT Margin peaked at 23.25% in Q3 2024 and troughed at 31.35% in Q3 2025.
- A 5-year average of 0.6% and a median of 1.29% in 2022 frame the typical range for EBIT Margin.
- The widest annual swing landed in 2024, when EBIT Margin jumped 2638 bps; it then sank 5460 bps in 2025.
- A 5-year view of EBIT Margin shows it stood at 20.52% in 2022, then tumbled by 103 bps to 0.61% in 2023, then surged by 2128 bps to 12.29% in 2024, then plunged by 115 bps to 1.86% in 2025, then tumbled by 1322 bps to 26.46% in 2026.
- Per Business Quant data, the three most recent EBIT Margin figures were 26.46% in Q2 2026, 1.86% in Q4 2025, and 31.35% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.38 Bn | 185.39 Mn | -26.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.46% |
| Dec 31, 2025 | -1.86% |
| Sep 30, 2025 | -31.35% |
| Jun 30, 2025 | 7.34% |
| Mar 31, 2025 | -6.85% |
| Dec 31, 2024 | 12.29% |
| Sep 30, 2024 | 23.25% |
| Jun 30, 2024 | 13.41% |
| Mar 31, 2024 | -2.20% |
| Dec 31, 2023 | -0.61% |
| Sep 30, 2023 | 5.29% |
| Jun 30, 2023 | -12.97% |
| Mar 31, 2023 | 3.37% |
| Dec 31, 2022 | 20.52% |
| Sep 30, 2022 | -0.86% |
| Jun 30, 2022 | 6.67% |
| Mar 31, 2022 | 1.29% |
| Dec 31, 2021 | 3.83% |
| Sep 30, 2021 | 21.96% |
| Jun 30, 2021 | 24.14% |